We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
Cap. Flow
+$71.5M
Cap. Flow %
2.43%
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12
Avg Time Held
0.9 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$85.5M
2
QURE icon
uniQure
QURE
+$52M
3
LH icon
Labcorp
LH
+$50.7M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$46.9M
5
IFRX icon
InflaRx
IFRX
+$40.6M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$78.7M
2
PBYI icon
Puma Biotechnology
PBYI
+$74.6M
3
PEN icon
Penumbra
PEN
+$67.6M
4
ABT icon
Abbott
ABT
+$39.2M
5
RGNX icon
Regenxbio
RGNX
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.2%
2 Miscellaneous 1.77%
3 Financials 1.03%
4 Technology 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CBAY icon
26
DELISTED
Cymabay Therapeutics
CBAY
$39.7M 1.35%
2,957,765
+2,200
+0.1% +$27.5K
2017 Q3
3 quarters
MOR icon
27
DELISTED
MorphoSys AG American Depositary Shares
MOR
$38.5M 1.31%
+1,269,800
New +$34.9M
2018 Q2
0 quarters
ANAB icon
28
AnaptysBio
ANAB
$1.42B
$36.9M 1.25%
519,250
-3,900
-0.7% -$327K
2017 Q4
2 quarters
HSKA
29
DELISTED
Heska Corp
HSKA
$36.8M 1.25%
354,776
+116,330
+49% +$10.9M
2017 Q4
2 quarters
UNH icon
30
UnitedHealth
UNH
$369B
$35.1M 1.19%
143,020
-2,400
-2% -$576K
2016 Q3
7 quarters
ELV icon
31
Elevance Health
ELV
$93.2B
$34.8M 1.18%
+146,000
New +$33.8M
2018 Q2
0 quarters
CBIO icon
32
Crescent Biopharma
CBIO
$482M
$32.7M 1.11%
20,293
-2,530
-11% -$4.35M
2017 Q2
4 quarters
IRTC icon
33
iRhythm Holdings
IRTC
$3.55B
$32.6M 1.11%
401,303
-328,571
-45% -$23M
2017 Q2
4 quarters
EHTH icon
34
eHealth
EHTH
$18.8M
$30.5M 1.03%
1,377,895
+47,400
+4% +$914K
2016 Q4
6 quarters
OXFD
35
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$28.8M 0.98%
2,235,207
-234,480
-9% -$3.17M
2013 Q4
18 quarters
NITE icon
36
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$28.6M 0.97%
1,785,446
+16,500
+0.9% +$235K
2017 Q3
3 quarters
CTLT icon
37
DELISTED
CATALENT, INC.
CTLT
$27.7M 0.94%
+661,850
New +$26.7M
2018 Q2
0 quarters
ABT icon
38
Abbott
ABT
$182B
$27.4M 0.93%
449,300
-646,800
-59% -$39.2M
2017 Q4
2 quarters
EPZM
39
DELISTED
Epizyme, Inc
EPZM
$27.4M 0.93%
2,021,389
+9,400
+0.5% +$146K
2017 Q3
3 quarters
SRRK icon
40
Scholar Rock
SRRK
$5.02B
$27.3M 0.93%
+1,750,408
New +$32.8M
2018 Q2
0 quarters
ELGX
41
DELISTED
Endologix Inc
ELGX
$24.5M 0.83%
432,639
-159,677
-27% -$8.1M
2015 Q4
10 quarters
TFX icon
42
Teleflex
TFX
$5.34B
$21.4M 0.73%
79,886
-96,700
-55% -$25.9M
2017 Q3
3 quarters
ZTS icon
43
Zoetis
ZTS
$32.6B
$21.2M 0.72%
+249,100
New +$21M
2018 Q2
0 quarters
CMRX icon
44
DELISTED
Chimerix, Inc.
CMRX
$17.1M 0.58%
3,589,490
-139,200
-4% -$665K
2016 Q2
8 quarters
SYRS icon
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$16.7M 0.57%
163,124
-2,100
-1% -$260K
2016 Q2
8 quarters
TCDA
46
DELISTED
Tricida, Inc. Common Stock
TCDA
$14.9M 0.51%
+500,000
New +$14M
2018 Q2
0 quarters
ODT
47
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$13.5M 0.46%
610,600
+16,400
+3% +$382K
2017 Q4
2 quarters
TDOC icon
48
Teladoc Health
TDOC
$1.07B
$13.4M 0.46%
231,000
-42,200
-15% -$2.06M
2017 Q4
2 quarters
PEN icon
49
Penumbra
PEN
$12.6B
$9.97M 0.34%
72,170
-474,909
-87% -$67.6M
2015 Q3
11 quarters
JNCE
50
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.3M 0.32%
1,214,593
+32,200
+3% +$464K
2017 Q1
5 quarters
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2018 Portfolio in Review

As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
  • Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
  • Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
  • Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
  • Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
  • Redmile Group opened 27 new positions and closed 12 in Q2 2018.
  • Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.

Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.